Please login to the form below

Not currently logged in
Email:
Password:

Symphogen

This page shows the latest Symphogen news and features for those working in and with pharma, biotech and healthcare.

Baxalta makes $1.7bn play for slice of CAR-T market

Baxalta makes $1.7bn play for slice of CAR-T market

The deal comes a few weeks after Baxalta agreed a deal with Symphogen worth up to $1.6bn to develop a series of novel checkpoint inhibitor drugs, making a bold foray

Latest news

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    Meanwhile, eyebrows were raised earlier this month when Baxalta signed a $1.6bn deal with Symphogen in oncology - which is not a major focus of either of the merging companies although

  • Baxalta inks $1.6bn immuno-oncology deal with Symphogen Baxalta inks $1.6bn immuno-oncology deal with Symphogen

    Baxalta inks $1.6bn immuno-oncology deal with Symphogen. Comes as the company's takeover negotiations with Shire continue. ... Copenhagen-based Symphogen said the first of the six candidates will start clinical testing in 2017 and that it would be

  • Merck KGaA acquires cancer drug from Symphogen Merck KGaA acquires cancer drug from Symphogen

    Merck KGaA acquires cancer drug from Symphogen. Will pay up to 495m for investigational metastatic colorectal cancer treatment. ... Merck KGgA has acquired to global rights to Symphogen's investigational cancer antibody Sym004 in a deal worth up to 495m.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2016 Deal Watch January 2016

    Only days before this, Baxalta had announced the investment of $175m upfront in a strategic collaboration with Symphogen taking the company into the ever popular field of oncology (headline deal value ... upfront. 1, 900. Symphogen/ Baxalta.

  • Pharma deals during September 2012 Pharma deals during September 2012

    In its search for a follow-on to Erbitux, Merck KGaA has taken an exclusive worldwide licence to Symphogen's Sym004, currently in phase I/II trials, for the treatment of ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics